MedTrace Logo

A PK Study of Oraxol in Breast Cancer Patients

NCT04993040 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-08-06

No results posted yet for this study

Summary

This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer patients for whom paclitaxel treatment is indicated.

Conditions

  • Breastcancer

Interventions

DRUG

Oraxol

* HM30181 methanesulfonate monohydrate * Oral paclitaxel capsules

Sponsors & Collaborators

  • Athenex, Inc.

    lead INDUSTRY

Principal Investigators

  • Erwei Song, Pro.f · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  • Herui Yao, Pro.f · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-22
Primary Completion
2019-12-09
Completion
2020-12-09
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04993040 on ClinicalTrials.gov